Argenx

Go or no go? Key FDA decisions for Argenx and Regeneron
Go or no go? Key FDA decisions for Argenx and Regeneron
EP Vantage
FDA
Albireo Pharma
Aldeyra Therapeutics
Alvotech
Amneal Pharmaceuticals
Argenx
ARS Pharmaceuticals
AstraZeneca
Bayer
Bio-Thera Solutions
Biogen
BioMarin Pharmaceutical
Bristol Myers Squibb
Eisai
Eton Pharmaceuticals
F2G
Fabre-Kramer Pharmaceuticals
Fresenius
GSK
Intercept Pharmaceuticals
Ipsen
Ironwood Pharmaceuticals
Merck
Novaliq
Pfizer
Regeneron
Roche
Sanofi
Sarepta Therapeutics
Shionogi
Swedish Orphan Biovitrum
Takeda
Teva Pharmaceutica
UCB Pharma
Flag link:
Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas
Argenx, Genmab pool expertise on antibody discovery, joining forces to expand into new therapeutic areas
Fierce Biotech
Genmab
Argenx
antibody discovery
drug discovery
cancer
immunology
Flag link:
OncoVerity eyes cusatuzumab development in AML after licensing rights
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
OncoVerity
Argenx
AML
cusatuzumab
Flag link:
Biotech heads towards big catalysts
Biotech heads towards big catalysts
EP Vantage
biotech
clinical trials
Alnylam Pharmaceuticals
Arcus Biosciences
Argenx
Arrowhead Pharmaceuticals
Axsome Therapeutics
Bavarian Nordic
FibroGen
Gilead Sciences
Incyte
Morphic Therapeutic
PTC Therapeutics
Syndax Pharmaceuticals
Travere Therapeutics
Vaxcyte
Flag link:
The world needs Garp, according to Abbvie
The world needs Garp, according to Abbvie
EP Vantage
AbbVie
GARP
Argenx
R&D
Flag link:
Biotech’s key upcoming clinical results
Biotech’s key upcoming clinical results
EP Vantage
clinical trials
Acadia Pharmaceuticals
Argenx
Arrowhead Pharmaceuticals
Biomarin
BioNTech
Daiichi Sankyo
Day One
EQRx
Fate Therapeutics
FibroGen
Gilead Sciences
Idorsia
Immunogen
Intellia Therapeutics
Karuna Therapeutics
Moderna Therapeutics
Regeneron
Roche
Travere Therapeutics
Vaxcyte
Flag link:
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
J&J’s next myeloma drug, Argenx’s second act and a new question for Bluebird: 3 ASH takeaways
BioPharma Dive
ASH 2022
JNJ
talquetamab
Multiple Myeloma
Argenx
Bluebird Bio
Vyvgart
ITP
Flag link:
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
ASH: With immune thrombocytopenia win, argenx proves efgartigimod's no one-trick pony in autoimmune disease
Fierce Pharma
ASH 2022
ITP
efgartigimod
Argenx
Flag link:
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Bluebird Bio Sells Priority Review Voucher For $102M, Strengthening Its Financial Position
Benzinga
Bluebird Bio
priority review vouchers
FDA
Argenx
Flag link:
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
Argenx Scores Priority Review for Generalized Myasthenia Gravis Therapeutic
BioSpace
Argenx
FDA
priority reviews
myasthenia gravis
efgartigimod
Flag link:
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Seeking sibling for Vyvgart, argenx files for FDA approval of subcutaneous efgartigimod
Fierce Pharma
Argenx
Vyvgart
myasthenia gravis
efgartigimod
FDA
Flag link:
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
As Vyvgart launch gains steam, Argenx CEO says his company can achieve 'standalone' success
Fierce Pharma
Argenx
Vyvgart
innovation
myasthenia gravis
Flag link:
Argenx takes a step towards convenience
Argenx takes a step towards convenience
EP Vantage
Argenx
efgartigimod
Vyvgart
myasthenia gravis
Flag link:
Argenx's Vygart launch finds quick neurologist support over AstraZeneca's well-entrenched Soliris for myasthenia gravis
Argenx's Vygart launch finds quick neurologist support over AstraZeneca's well-entrenched Soliris for myasthenia gravis
Fierce Pharma
Argenx
Vygart
myasthenia gravis
neurologists
Flag link:
Go or no go? Argenx's December showdown
Go or no go? Argenx's December showdown
EP Vantage
FDA
Argenx
efgartigimod
myasthenia gravis
Calliditas
Nefcon
Merck
Keytruda
Flag link:
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
From Pfizer to Argenx: A look at potential blockbusters awaiting FDA decisions this year
Fierce Pharma
FDA
Pfizer
Argenx
UCB Pharma
Roche
efgartigimod
bimekizumab
faricimab
abrocitinib
Flag link:
The big approvals still on the cards for 2021
The big approvals still on the cards for 2021
EP Vantage
FDA
drug approvals
Argenx
Novartis
AstraZeneca
Astellas
UCB Pharma
Ascendis Pharma
ChemoCentryx
Axsome Therapeutics
Flag link:
Johnson & Johnson culls $1.6B argenx blood cancer drug collab
Johnson & Johnson culls $1.6B argenx blood cancer drug collab
Fierce Biotech
JNJ
biobucks
Belgium
Argenx
cusatuzumab
Flag link:
AgomAb raises $74M to develop regenerative pathway modulators
AgomAb raises $74M to develop regenerative pathway modulators
Fierce Biotech
AgomAb
regenerative pathway modulators
Argenx
Flag link:
Aducanumab tops 2021’s biggest potential launches
Aducanumab tops 2021’s biggest potential launches
EP Vantage
drug launches
Biogen
Eisai
aducanumab
efgartigimod
Argenx
Evrenzo
FibroGen
Astellas
AstraZeneca
Leqvio
Novartis
UCB Pharma
bimekizumab
Ascendis Pharma
Bluebird Bio
Bristol-Myers Squibb
ide-cel
liso-cel
AXS-05
Axsome Therapeutics
voclosporin
Aurinia
Flag link:

Pages